Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

4.760 +0.250 (+5.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,002,057
Open 4.500
Bid (Size) 4.740 (1)
Ask (Size) 4.780 (2)
Prev. Close 4.510
Today's Range 4.470 - 4.775
52wk Range 1.680 - 5.125
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Ardelyx
Via Benzinga
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire

Performance

YTD
+77.61%
+77.61%
1 Month
+18.70%
+18.70%
3 Month
+3.70%
+3.70%
6 Month
+21.43%
+21.43%
1 Year
+157.30%
+157.30%

More News

Read More
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023
Via InvestorPlace
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Why Ardelyx Stock Soared Today
Via The Motley Fool
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
Via Benzinga
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
3 Penny Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Ardelyx Stock Popped Today
Via The Motley Fool
Exposures Product Safety
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Crude Oil Rises Sharply; Ardelyx Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
Workhorse (WKHS) Stock Jumps on Drone Business Success
Via InvestorPlace
FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug
Via InvestorPlace
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.